Smartlab Europe

Press Releases

Anti-Cancer Agent vastin ,Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer

Chugai Pharmaceutical Co Ltd announced that it gained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 23, 2016, for “advanced or recurrent cervical cancer,” as new additional indication for the anti-cancer agent / anti-VEGF...

Astellas Pharma Inc , Daiichi Sankyo, and Takeda Announce Research Collaboration on Establishing Biomarker Database on Healthy Adults

Three Pharmaceutical Companies with Research Bases in Japan Work Together to Accelerate Innovation in Japan-Originated Drug Discovery Astellas Pharma Inc ,Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Company Limited announced that they have entered into a...

Kyowa Hakko Kirin Announces Commencement of Phase 2 Clinical Study of RTA 402 in CKD patients with type 2 diabetes in Japan

Bardoxolone Methyl (RTA 402) Data Show Improvement in Renal Function by Inulin Clearance in a Phase II Clinical Study in Japan Kyowa Hakko Kirin Co., Ltd. (Tokyo; 4151 President and CEO: Nobuo Hanai; “Kyowa Hakko Kirin”). ...

CHAMPIX European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP

Pfizer Inc announced that the European Summary of Product Characteristics (SmPC) and Package Leaflet for CHAMPIX® (varenicline) have been updated to include safety and efficacy data from the EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial....

Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing

Aims to identify maladaptive brain circuits to find new approaches for treating psychiatric diseases Second Boehringer Ingelheim crowdsourcing project with BioMed X builds on success of previous project focused on epigenetic drivers of COPD New research team...

Mylan NV Launches First Generic Doryx Delayed-Release Tablets, 200 mg

Mylan N.V. announced the U.S. launch of Doxycycline Hyclate Delayed-Release (DR) Tablets USP, 200 mg, a generic version of Mayne's Doryx®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental...

Gather China & World Pharmaceutical Entrepreneurs,Create a New Chapter of Chinese Pharma Industry

CPhI& P-MEC China will be held in Shanghai New International Expo Center on June 21-23, 2016.Bearing 15-year trust of the industry, CPhI& P-MEC China continuously lead the development of the Chinese pharmaceuticalindustry, and construct a global one-stop pharmaceutical industrial...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »